BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.